<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078855</url>
  </required_header>
  <id_info>
    <org_study_id>66593</org_study_id>
    <nct_id>NCT03078855</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma</brief_title>
  <acronym>ILyAD</acronym>
  <official_title>ILyAD (Indolent Lymphoma And Vitamin D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Friedberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable
      outcomes in patients with numerous cancers, there has never been a thorough study of vitamin
      D treatment in subjects undergoing treatment for cancer. The purpose of this study is to
      evaluate whether modification of vitamin D levels in the blood, through supplementation, can
      improve outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression or death</measure>
    <time_frame>Year three</time_frame>
    <description>Mean time to death or progression defined as increase in lymphoma burden by at least 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to death</measure>
    <time_frame>Year three</time_frame>
    <description>Mean time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to rituximab defined as reduction of lymphoma burden by at least 50%</measure>
    <time_frame>13 weeks</time_frame>
    <description>Response is defined as reduction of lymphoma burden by at least 50%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Mucosal-Associated Lymphoid Tissue Lymphoma</condition>
  <arm_group>
    <arm_group_label>Vitamin D plus rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus rituximab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>vitamin D3 2,000 IU daily</description>
    <arm_group_label>Vitamin D plus rituximab</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 intravenous weekly</description>
    <arm_group_label>Vitamin D plus rituximab</arm_group_label>
    <arm_group_label>Placebo plus rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>methylcellulose</description>
    <arm_group_label>Placebo plus rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each of the following criteria must be met in order for a patient to be considered
        eligible for registration:

          -  Biopsy proven (with hematopathology review at one of the participating sites to
             confirm correct histology in accordance with World Health Organization) indolent
             lymphoma to include the following diagnoses:

               -  Grade 1, 2, or 3a follicular lymphoma

               -  Small lymphocytic lymphoma (CLL excluded)

               -  Marginal zone lymphoma (nodal or splenic)

               -  Mucosal-associated lymphoid tissue

          -  No prior anti-lymphoma systemic therapy; prior radiation therapy allowed

          -  Age 18 or over

          -  Ann Arbor stages II, III or IV

          -  Patients with follicular lymphoma must fulfill Low tumor burden by Groupe D'Etude des
             Lymphomes Folliculaires (GELF) criteria:

               -  Measurable disease defined by the Lugano criteria

               -  No mass &gt; 7 cm

               -  &lt; 3 distinct masses of greater than 3 cm

               -  No B symptoms

               -  No splenomegaly &gt; 16 cm by computed tomography (CT) scan

               -  No risk of vital organ compression

               -  No leukemic phase &gt; 5000/µl circulating lymphocytes (except for in patients with
                  splenic marginal zone diagnosis)

               -  No cytopenias (platelets &lt; 100,000/µl, hemoglobin &lt; 10 g/dl, or absolute
                  neutrophil count &lt; 1500/µl)

        Exclusion Criteria:

        The following criteria will prevent inclusion of an inappropriate subject into the trial:

          -  Osteoporosis requiring prescription treatment

          -  Known symptomatic hyperparathyroidism

          -  Hypercalcemia (defined as above the institutional normal range)

          -  History of calcium-related kidney stones

          -  Creatinine &gt; 2X above upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erin M Cebula, MPH</last_name>
    <phone>585-275-3883</phone>
    <email>Erin_Cebula@urmc.rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 8, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jonathan Friedberg</investigator_full_name>
    <investigator_title>Director, Wilmot Cancer Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
